TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25733467
Drug: Biofortified maize
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofortified maize (34 μg zinc/g grain)
Study: 25733467
Drug: Fortified maize
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortified maize (60 μg zinc/g)
Study: 25733467
Drug: Control maize
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control maize (21 μg zinc/g)
Study: 17277392
Drug: Protein kinase
Normalized name: Protein kinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein kinase C inhibitors
Study: 17277392
Drug: Intravitreal steroid
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal steroid injections
Study: 17277392
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone inhibitors
Study: 1562756
Drug: Aldose reductase
Normalized name: Aldose reductase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldose reductase inhibitors
Study: 17277392
Drug: Advanced glycation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advanced glycation end-products inhibitors
Study: 8239106
Drug: Continuous nebulization
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous nebulization of 30 mg albuterol over 110 minutes
Study: 8239106
Drug: Intermittent nebulization
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent nebulization of 30 mg albuterol over 110 minutes
Study: 8239106
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Continuous and Intermittent nebulization)
Study: 3116985
Drug: Nicardipine 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 50 mg b.i.d. for 3 weeks
Study: 12614743
Drug: High‐dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High‐dose intravenous methylprednisolone pulse therapy (1 g per day for 3 successive days, repeated 3 times within 3 weeks) followed by 24‐Gy orbital radiotherapy
Study: 12614743
Drug: High‐dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High‐dose intravenous methylprednisolone pulse therapy without orbital radiotherapy
Study: 1663163
Drug: lisinopril (10‐40
Approvals — FDA: no, EMA: no, PMDA: no
Description: lisinopril (10‐40 mg)
Study: 1663163
Drug: enalapril (5‐20
Approvals — FDA: no, EMA: no, PMDA: no
Description: enalapril (5‐20 mg)
Study: 7160424
Drug: Effervescent tablets
Normalized name: Hydralyte Effervescent Tablets Berry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effervescent tablets (1200 mg)
Study: 7160424
Drug: Enteric coated
Normalized name: Mesasal Enteric Coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric coated tablets (650 mg)
Study: 7160424
Drug: Sodium salicylate
Normalized name: Sodium Salicylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium salicylate (1.0 g)
Study: 31399147
Drug: FIT039-releasing transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: FIT039-releasing transdermal patch
Study: 28130749
Drug: Intravenous azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous azithromycin (IA) + methylprednisolone
Study: 28130749
Drug: Intravenous azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous azithromycin (IA) + IVIG
Study: 28130749
Drug: Intravenous azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous azithromycin (IA) + methylprednisolone (group C1)
Study: 28130749
Drug: Intravenous azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous azithromycin (IA) + IVIG (group C2)
Study: 28130749
Drug: Intravenous azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous azithromycin (IA) alone (group C)
Study: 24822268
Drug: Levamisole (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole (50 mg) and low-dose prednisolone (5 mg)
Study: 21728748
Drug: Occlusal splint
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occlusal splint therapy for 6 months
Study: 11439206
Drug: Accelerated radiotherapy
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated radiotherapy (ART) - 1.8 Gy twice a day to a dose of 59.4 Gy in 33 fractions over 24 days
Study: 11439206
Drug: Conventional radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional radiotherapy (CRT) - 2 Gy/day to a dose of 70 Gy in 35 fractions over 49 days
Study: 773801
Drug: Sulpiride (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride (100 mg i.m. twice daily for 12 days, then 50 mg orally three times daily for 48 days)
Study: 28606000
Drug: Trauma-focused cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trauma-focused cognitive behavior therapy
Study: 27558585
Drug: Meratrim (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meratrim (400 mg twice daily)
Study: 22631032
Drug: ASA 81
Normalized name: ASA 81 MG Oral Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA 81 mg
Study: 22631032
Drug: ASA 81
Normalized name: ASA 81 MG Oral Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA 81 mg + esomeprazole 20 mg
Study: 19553142
Drug: Atorvastatin (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (10-20 mg once per day for 12 weeks)
Study: 16619571
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg oral pilocarpine 3 times a day during radiotherapy for 12 weeks
Study: 10781275
Drug: Propofol plus
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol plus alfentanil 100 ng/ml
Study: 6355247
Drug: IPG (immunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPG (immunotherapy with polymerized whole grass)
Study: 27075909
Drug: LD +
Normalized name: Children's Tylenol Cold + Flu
Approvals — FDA: no, EMA: no, PMDA: no
Description: LD + MCT (l‐leucine 1.2 g, cholecalciferol 20 μg, 6 g medium‐chain triglycerides)
Study: 27075909
Drug: LD +
Normalized name: Children's Tylenol Cold + Flu
Approvals — FDA: no, EMA: no, PMDA: no
Description: LD + LCT (l‐leucine 1.2 g, cholecalciferol 20 μg, 6 g long‐chain triglycerides)
Study: 22080632
Drug: C1‐esterase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: C1‐esterase inhibitor infusion (12,000 U) in addition to conventional treatment
Study: 22080632
Drug: C1‐esterase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: C1‐esterase inhibitor infusion
Study: 19535971
Drug: Atenolol 25
Normalized name: atenolol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 25 mg/amlodipine 2.5 mg
Study: 19535971
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg/amlodipine 5 mg
Study: 19535971
Drug: Atenolol 25
Normalized name: atenolol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 25 mg alone
Study: 19535971
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg alone
Study: 19535971
Drug: Atenolol/amlodipine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol/amlodipine combination
Study: 15872126
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg iv given at the end of surgery
Study: 12566894
Drug: 1-hour paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1-hour paclitaxel infusion
Study: 10550134
Drug: 3-hour paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3-hour paclitaxel infusion
Study: 8664454
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg BN52021 (paf-receptor antagonist) injected twice just before vascular cannulation and before cross-clamp release
Study: 2363546
Drug: 3 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg.kg‐1 propofol
Study: 2363546
Drug: 3 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg.kg‐1 propofol + 1.5 mg.kg‐1 suxamethonium
Study: 369925
Drug: oxaprozin 600
Normalized name: oxaprozin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxaprozin 600 mg/day
Study: 369925
Drug: oxaprozin 1200
Normalized name: Oxaprozin
DrugBank: Oxaprozin (DB00991)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oxaprozin 1200 mg/day
Study: 369925
Drug: aspirin 3900
Normalized name: aspirin 3900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: aspirin 3900 mg/day
Study: 25963394
Drug: Expressive writing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expressive writing treatments focusing on trauma, sexuality, or daily life (control condition)
Study: 15041597
Drug: Lidocaine 2%
Normalized name: LIDOCAINE 2% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 2% (bolus injection of 1.5 mg/kg in 10 min followed by an IV infusion of 1.5 mg/kg/h)
Study: 11765119
Drug: Empiric use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empiric use of GP IIb/IIIa inhibitors
Study: 8998092
Drug: i.v. diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. diltiazem and i.v. digoxin (combination)
Study: 3539821
Drug: Doxycycline, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline, 100 mg/day for 1 month
Study: 30744517
Drug: Transcranial Pulsed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial Pulsed Electromagnetic Fields (active treatment)
Study: 20523050
Drug: Rivastigmine 3-12
Normalized name: rivastigmine 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivastigmine 3-12 mg/day (capsules bid)
Study: 11063155
Drug: Low SPGI
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low SPGI levels (< 25 microg/l) with diagnostic gastroscopy
Study: 11063155
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with SPGI >= 50 microg/l
Study: 11063155
Drug: Curative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curative treatment for early cancer or high-grade dysplasia
Study: 2423800
Drug: Indoramin (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoramin (50-100 mg/day)
Study: 2423800
Drug: Pindolol (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (10-20 mg/day)
Study: 12723743
Drug: Ibuprofen lysine
Normalized name: Ibuprofen Lysine
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen lysine
Study: 29667449
Drug: Ibuprofen liquid
Normalized name: ibuprofen Oral Liquid Product
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen liquid capsule
Study: 26819724
Drug: Ibuprofen sodium
Normalized name: Ibuprofen sodium
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen sodium
Study: 29667449
Drug: Ibuprofen acid
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen acid (reference)
Study: 29667449
Drug: Ibuprofen salts
Normalized name: ibuprofen, sodium salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen salts (overall)
Study: 24420549
Drug: Intranasal angiotensin
Normalized name: Angiotensin 1-7
DrugBank: Angiotensin 1-7 (DB11720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal angiotensin II (400 μg)
Study: 20872550
Drug: No concomitant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No concomitant treatment (Control)
Study: 19996984
Drug: Fospropofol 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fospropofol 2 mg/kg
Study: 18194506
Drug: Fospropofol 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fospropofol 5 mg/kg
Study: 19996984
Drug: Fospropofol 6.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fospropofol 6.5 mg/kg
Study: 18194506
Drug: Fospropofol 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fospropofol 8 mg/kg
Study: 17189550
Drug: Antioxidant (AOX)
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant (AOX) treatment (800 IU of vitamin E, 500 mg of vitamin C, 10 mg of beta-carotene)
Study: 17189550
Drug: Antioxidant (AOX)
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant (AOX) treatment
Study: 29807257
Drug: Dilute vinegar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilute vinegar lavage (20 mL of vinegar in 1 L saline) every second day during each estrus period (n=4)
Study: 18569272
Drug: 3% diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% diclofenac gel applied once daily
Study: 18569272
Drug: 5% imiquimod
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% imiquimod cream applied three times a week for 12 weeks
Study: 16048853
Drug: Integrated, multifaceted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated, multifaceted depression treatment model
Study: 11831837
Drug: Antioxidant vitamin
Normalized name: antioxidant vitamins with minerals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant vitamin cocktail (650 mg vitamin E, 250 mg vitamin C, 20 mg beta-carotene)
Study: 7015172
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose subcutaneous heparin
Study: 29914300
Drug: Prism adaptation
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prism adaptation with concurrent exposure
Study: 30374818
Drug: 41.4 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 41.4 Gy (low-dose)
Study: 30374818
Drug: 50.4 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50.4 Gy (high-dose)
Study: 30374818
Drug: 45 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 Gy (moderate-dose)
Study: 26188541
Drug: Metformin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin treatment in type 2 diabetes patients
Study: 21488751
Drug: Atomoxetine (ATX)
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atomoxetine (ATX) fast: 7 days at 0.5 mg/kg, then 1.2 mg/kg
Study: 21488751
Drug: Atomoxetine (ATX)
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atomoxetine (ATX) slow: 7 days each at 0.5 and 0.8 mg/kg, then 1.2 mg/kg
Study: 29845723
Drug: Imarikiren 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imarikiren 5 to 200 mg
Study: 29845723
Drug: Imarikiren 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imarikiren 50 mg (Food Effect part)
Study: 27025129
Drug: Remaxol at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remaxol at a dose of 800 mg/day for 7 days
Study: 22884767
Drug: Exenatide QW
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide QW (2 mg)
Study: 12207128
Drug: 0.05 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg/kg piritramide intravenously (group A)
Study: 1849152
Drug: Antacid (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid (30 mL Maalox) with 500 mg azithromycin
Study: 1849152
Drug: Cimetidine (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (800 mg) 2 hours before 500 mg azithromycin
Study: 1849152
Drug: Placebo before
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo before 500 mg azithromycin
Study: 6639916
Drug: Fish-oil concentrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish-oil concentrate (MaxEPA), 10 g daily for 2 weeks
Study: 6639916
Drug: Vegetable oil
Normalized name: Vegetable Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vegetable oil supplement, 10 g daily for 2 weeks
Study: 25388552
Drug: Patient education
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient education combined with exercise therapy (supervised exercises 3 times/week for 3 months)
Study: 25388552
Drug: Patient education
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient education combined with exercise therapy
Study: 16911633
Drug: Nicotinamide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinamide (25 mg/kg daily)
Study: 3330988
Drug: Nifedipine/diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine/diuretic
Study: 3330988
Drug: Placebo/diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo/diuretic
Study: 27608206
Drug: Fractional microneedling
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional microneedling radiofrequency (FMR) treatment on one side of the cheeks, two sessions with a 4-week interval.
Study: 20300033
Drug: Method D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Method D (5 minutes of jogging and a combination of static stretching and dynamic exercise)
Study: 19378580
Drug: Infragluteal sciatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infragluteal sciatic nerve block (Group 1) with 30 mL of 0.5% bupivacaine (S75/R25) with 1:200,000 epinephrine
Study: 19378580
Drug: Parasacral sciatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parasacral sciatic nerve block (Group 2) with 30 mL of 0.5% bupivacaine (S75/R25) with 1:200,000 epinephrine
Study: 8630631
Drug: Meloxicam 7.5
Normalized name: meloxicam 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam 7.5 mg and Meloxicam 15 mg
Study: 1465080
Drug: Low protein
Normalized name: Low protein mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low protein intake (0.8‐1.1 g/kg/day)
Study: 23076450
Drug: Aliskiren/amlodipine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren/amlodipine combination therapy
Study: 19207891
Drug: Subantimicrobial dose
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subantimicrobial dose doxycycline (SDD) 20 mg b.i.d. + surgery
Study: 17086096
Drug: Prednisone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (1 mg/kg/day with a maximum dose of 60 mg/day)
Study: 31472039
Drug: High circulating
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High circulating dipeptidyl peptidase 3 (cDPP3) group (cDPP3 ≥59.1 ng/mL) at inclusion
Study: 29600897
Drug: Intravenous esmolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous esmolol (β1‐adrenergic receptor antagonist)
Study: 26613591
Drug: Glucose metabolism
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose metabolism and body composition measures
Study: 18986282
Drug: Oral antibacterial
Normalized name: Dermoplast Antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antibacterial drugs
Study: 18986282
Drug: Intravenously administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenously administered antibacterial drugs
Study: 10390914
Drug: Low-dose acetylsalicylic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose acetylsalicylic acid (ASA) (1.5 mg/kg)
Study: 10390914
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (Sadamin, Partusisten, glucose i.v., amino acids i.v.)
Study: 8686047
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with gold and penicillamine
Study: 6286089
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with periodic reinductions
Study: 8294223
Drug: Naltrexone 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone 25 mg/day for 4 weeks followed by 50 mg/day for 4 weeks
Study: 3505536
Drug: Brand A
Normalized name: Select Brand Aspirin 325mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brand A salbutamol metered-dose inhaler (MDI)
Study: 3505536
Drug: Brand B
Normalized name: Select Brand Bulk-Forming Laxative Powder for Suspension (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brand B salbutamol metered-dose inhaler (MDI)
Study: 25054392
Drug: Tapentadol PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol PR (100 - 250 mg bid)
Study: 25054392
Drug: Morphine CR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine CR (40 - 100 mg bid)
Study: 25054392
Drug: Morphine CR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine CR
Study: 16192367
Drug: Ibuprofen (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (400 mg qid for 2 days)
Study: 16192367
Drug: Rofecoxib (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib (25 mg once a day for 5 days)
Study: 8625171
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of 5-FU (1000 mg/m2, days 1-4) with bolus FA (200 mg/m2, days 1-4)
Study: 8625171
Drug: Bolus 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bolus 5-FU (375 mg/m2, days 1-5) with bolus FA (200 mg/m2, days 1-5)
Study: 2404768
Drug: Nimodipine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine (30 mg q.i.d. orally for 14 days)
Study: 29260401
Drug: Post-exercise protein
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-exercise protein supplementation made from cow's milk (13 g of proteins)
Study: 16238896
Drug: IV metamizol
Normalized name: Metamizole
DrugBank: Metamizole (DB04817)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV metamizol 1 g
Study: 12151921
Drug: Propofol at
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol at 600 ng/ml
Study: 12151921
Drug: Propofol at
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol at 1000 ng/ml
Study: 677431
Drug: Fentanyl (0.80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (0.80 mcg/kg body weight/10 min) and Flunitrazepam (1 mg)
Study: 677431
Drug: Naloxone (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.05 mg) administered postoperatively
Study: 7104154
Drug: pindolol 10
Normalized name: pindolol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: pindolol 10 mg three times daily for 4 weeks
Study: 7104154
Drug: metoprolol 100
Normalized name: metoprolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoprolol 100 mg three times daily for 4 weeks
Study: 31049085
Drug: Intravenous ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketorolac 0.9 mg/Kg
Study: 31049085
Drug: Intravenous nalbuphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nalbuphine 0.25 mg/Kg
Study: 26327289
Drug: Local treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local treatment focusing on quadriceps strengthening, quadriceps stretching, and taping for fortnight 1, supplemented with individualized global treatment focusing on lower limb posture and movement patterns for fortnight 2, followed by ongoing self-management.